British drugmaker GSK said on Thursday it would not be proceeding with regulatory submissions of its experimental treatment for moderate-to-severe rheumatoid arthritis (RA) after the drug failed to meet a key goal in a study.
In a late-stage study, the antibody-based drug, otilimab, did not make a meaningful difference to improving swelling and tenderness in joints to aid movement in patients who had not responded to other forms of treatment before.
“The limited efficacy demonstrated does not support a suitable benefit/risk profile for otilimab as a potential treatment for RA,” the company said in a statement.
